NCT02975336: Phase II Clinical Trial

From GM-RKB
(Redirected from NCT02975336)
Jump to navigation Jump to search

An NCT02975336: Phase II Clinical Trial is a randomized, double-blind, placebo-controlled dose-ranging Phase II clinical trial to evaluate the safety and efficacy of M2951 in subjects With Systemic Lupus Erythematosus (SLE).



References

2022